文献速递腹部介入CT

动态增强CT灌注成像在晚期肝细胞癌患者索拉非尼治疗肿瘤反应定量评估中的诊断价值:一项可行性研究

Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
PubMed 文献 · Eur J Radiol · 2017-02-20

22例晚期肝细胞癌患者在接受索拉非尼治疗前及治疗后2个月行256排MDCT灌注检查,定量测量靶病灶的灌注参数。根据mRECIST将患者分为应答组(17例)和无应答组(5例),应答组靶病灶的肝灌注和动脉灌注较治疗前显著降低,无应答组无显著变化。灌注CT技术可用于定量评估抗血管生成治疗相关的变化。

要点

  • 治疗前肝细胞癌病灶的各项平均灌注值均显著高于肝硬化实质。
  • 应答组靶病灶治疗后肝灌注和动脉灌注较治疗前显著降低,无应答组无显著变化。
  • 应答组中完全缓解者与部分缓解或稳定者的肝灌注百分比变化存在显著差异。

核心结论

  • 灌注CT技术可用于肝细胞癌抗血管生成治疗相关变化的定量评估;识别应答预测因素可能帮助临床医生筛选可能从靶向治疗中获益的患者,从而优化个体化治疗。

研究设计与样本

  • 可行性研究,纳入22例晚期肝细胞癌患者,使用256排MDCT扫描仪行灌注CT检查,于索拉非尼给药前及给药后2个月各检查一次,以mRECIST为参考标准将患者分为应答组和无应答组。

诊断标准与关键数值

  • 治疗前肝细胞癌病灶与肝硬化实质比较:肝灌注47.8±17.2 vs 13.3±6.3 mL/s per 100g,动脉灌注47.9±18.1 vs 12.9±10.7 mL/s,均p<0.001。应答组(n=17)靶病灶治疗后较治疗前:肝灌注29.2±23.3 vs 48.1±15.1,动脉灌注29.4±24.6 vs 49.2±17.4,均p<0.01;无应答组(n=5)治疗前后肝灌注46.9±25.1 vs 46.7±24.1,动脉灌注43.4±21.7 vs 43.5±24.6,无显著变化。应答组中完全缓解者(79%)与部分缓解或稳定者(16%)的肝灌注百分比变化(ΔHP)差异显著(p=0.04)。

临床应用与阅片要点

  • 灌注CT可定量测量肝细胞癌靶病灶的肝灌注、达峰时间、血容量、动脉灌注和肝灌注指数,用于评估索拉非尼治疗前后的血流动力学变化;阅片时需注意病灶与肝硬化实质的灌注值差异,并按mRECIST分类结合灌注参数变化判断应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the feasibility of perfusion-CT (p-CT) measurements in quantitative assessment of hemodynamic changes related to sorafenib in patients with advanced hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: Twenty-two patients with advanced HCC underwent p-CT study (256-MDCT scanner) before and 2 months after sorafenib administration. Dedicated perfusion software generated a quantitative map of arterial and portal perfusion and calculated the following perfusion parameters in target liver lesion: hepatic perfusion (HP), time-to-peak (TTP), blood volume (BV), arterial perfusion (AP), and hepatic perfusion index (HPI). After the follow-up scan, patients were categorized as responders and non-responders, according to mRECIST. Perfusion values were analyzed and compared in HCC lesions and in the cirrhotic parenchyma (n=22), such as between baseline and follow-up in progressors and non-progressors.

RESULTS: Before treatment, all mean perfusion values were significantly higher in HCC lesions than in the cirrhotic parenchyma (HP 47.8±17.2 vs 13.3±6.3mL/s per 100g; AP 47.9±18.1 vs 12.9±10.7mL/s; p<0.001). The group that responded to sorafenib (n=17) showed a significant reduction of values in HCC target lesions after therapy (HP 29.2±23.3 vs 48.1±15.1; AP 29.4±24.6 vs 49.2±17.4; p<0.01), in comparison with the non-responder group (n=5) that demonstrated no significant variation before and after treatment of HP (46.9±25.1 vs 46.7±24.1) and AP (43.4±21.7 vs 43.5±24.6). Among the responder group, HP percentage variation (Δ) in target lesions, during treatment, showed a significantly different (p=0.04) ΔHP in the group with complete response (79%) compared to the group with partial response or stable disease (16%).

CONCLUSIONS: p-CT technique can be used for HCC quantitative assessment of changes related to anti-angiogenic therapy. Identification of response predictors might help clinicians in selection of patients who may benefit from targeted-therapy allowing for optimization of individualized treatment.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ippolito D, Querques G, Okolicsanyi S, et al. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. Eur J Radiol. 2017. PMID: 28583645. doi:10.1016/j.ejrad.2017.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。